Herein, we propose a mechanism for the resistance of PDAC to anti-PD-1 and CTLA-4 immunotherapies and re-assess the rationale for pursuing T<sub>reg</sub>-targeted therapies in light of recent studies that profiled the immune landscape of patient-derived tumour samples. This evidence concerns the gene CTLA4 and neoplasm.